Pacira BioSciences to Present New Findings on EXPAREL
Pacira BioSciences, Inc. (NASDAQ: PCRX), a leader in innovative, non-opioid pain management solutions, is set to share its latest research at a key conference focused on health, pharmacy, and managed care in the near future. Their findings emphasize the effectiveness of EXPAREL® (bupivacaine liposome injectable suspension) in enhancing patient recovery while reducing reliance on opioids.
Engaging the Healthcare Community
The upcoming annual meeting intends to offer healthcare professionals a detailed look at new real-world data collected from the Innovations in Genicular Outcomes Registry (IGOR). This unique multicenter, prospective study aims to understand the outcomes of patients who underwent various pain management techniques, specifically focusing on the efficacy of EXPAREL.
Enhancing Patient Outcomes with Innovative Solutions
Jennifer Lin, Senior Director of Health Economics and Outcomes Research at Pacira BioSciences, expressed excitement about sharing the substantial impacts of postsurgical pain management research. By fostering a comprehensive understanding of multimodal pain pathways, Pacira aims to elevate patient care standards and potentially lower healthcare costs. This aligns with their overall mission to minimize opioid use in clinical settings.
Highlighted Presentations at the Conference
During the meeting, several key presentations will shed light on the following topics:
- Improved Patient Outcomes Post Total Knee Arthroplasty: An examination of intraoperative liposomal bupivacaine and its benefits regarding pain, opioid utilization, and hospital stays.
- Health Economic Outcomes Related to Outpatient Shoulder Arthroplasty: A comparative study on the effects of liposomal bupivacaine in Medicare-insured patients.
- Healthcare Resource Utilization for Total Knee Arthroplasty: Insights into how liposomal bupivacaine affects costs and resource use in ambulatory surgical centers.
About EXPAREL®
EXPAREL is designed to provide effective postsurgical analgesia through local infiltration for patients aged six and older. Its formulation uses multivesicular liposomes to release bupivacaine gradually, leading to prolonged pain relief while minimizing opioid consumption. Comprehensive data and studies affirm the unique benefits offered by EXPAREL, setting it apart as a premier choice in postoperative pain management.
Additional Insights into Pacira's Offerings
Beyond EXPAREL, Pacira also markets ZILRETTA® and offers the innovative iovera° device, showcasing their commitment to improving patient experiences across various medical specialties. Each of these solutions contributes to a broader strategy aimed at addressing the challenges posed by chronic and postoperative pain.
Frequently Asked Questions
What is EXPAREL?
EXPAREL is a long-acting local anesthetic used for postsurgical pain management, approved for various infiltration techniques.
How does EXPAREL reduce opioid usage?
By providing effective, sustained pain relief, EXPAREL allows for a significant reduction in the need for opioids.
Who is presenting at the AMCP Nexus 2025?
Experts from Pacira, including Jennifer Lin and Gabriel Wong, will present their findings on EXPAREL's efficacy.
What are the side effects of EXPAREL?
Common side effects may include nausea and constipation; however, it is generally well tolerated.
How can healthcare providers learn more about Pacira's products?
Providers can visit Pacira's official website or contact their representatives for detailed information and resources.
